secwatch.observer — SEC 8-K summary
======================================

Issuer:     Guardant Health, Inc. (GH)
CIK:        0001576280
Form:       8-K
Filed at:   2025-10-29T23:59:59+00:00
Accession:  0001576280-25-000276
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guardant Health Q3 revenue $265.2M (+39% YoY); raises FY2025 revenue guidance to $965-$970M
--------------------------------------------------------------------------------

- Q3 total revenue $265.2M (+39% YoY); GAAP net loss $92.7M ($0.74/share), non-GAAP net loss $48.3M ($0.39/share).
- Oncology revenue $184.4M (+31%), 74K tests (+40%); Shield screening revenue $24.1M (from $1M), 24K tests.
- FY2025 revenue guidance raised to $965-$970M (from $915-$925M), ~31% YoY growth; Screening rev guidance $71-$73M.
- Non-GAAP gross margin 66% (up from 63%); cash, equivalents and restricted cash $689.5M.
- Shield expanded to multi-cancer detection; Guardant360 Liquid PMA submitted to FDA; new collaborations with Quest and PathGroup.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000276/0001576280-25-000276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576280/000157628025000276/gh-20251029.htm
  HTML page:      https://secwatch.observer/filing/0001576280-25-000276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer